Industry News

• FDA announces new boxed warning on Plavix  The U.S. Food and Drug Administration added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.
  FDA March 12, 2010  
• Sanofi-aventis and BMS announce important updates to PLAVIX U.S. prescribing info  Sanofi-aventis U.S. and Bristol-Myers Squibb announced revisions to the U.S. prescribing information for PLAVIX(R) (clopidogrel bisulfate), which include a boxed warning.
  Bristol-Myers Squibb Company March 12, 2010  
• Monsanto welcomes chance to participate in Dept. of Justice/Dept. of Agriculture workshop  As part of today's first joint public workshop exploring competition issues in the agriculture industry, Monsanto will participate in a panel discussion about the past, present and future of the seed and trait industry.
  Monsanto Company March 12, 2010  
• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation March 12, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• CEL-SCI receives payment from marketing partner  CEL-SCI announced that it has received a $125,000 payment from Byron Biopharma under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company's cancer drug Multikine(R) in the Republic of South Africa.
  CEL-SCI Corporation March 10, 2010  
• Dr. Francis S. Collins receives Albany Medical Center Prize  NIH Director Francis S. Collins, M.D., Ph.D. has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in mapping the human genome.
  National Institutes of Health March 10, 2010  

   (next 10 articles)